Last updated: December 13, 2013
Sponsor: UCB Pharma
Overall Status: Completed
Phase
3
Condition
Allergy
Common Cold
Nasal Obstruction
Treatment
N/AClinical Study ID
NCT00525278
A00348
Ages 18-60 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Male or female, 18 to 60 years old, inclusive
two-year history of allergic rhinitis due to tree, grass or weed pollen
sufficient histamine-dependent symptoms of rhinitis during the selection week (T5SS ≥
Exclusion
Exclusion Criteria:
An ear, nose or throat (ENT) infection
asthma requiring daily drug therapy other than ß2 inhaled agonists taken prn
atopic dermatitis or urticaria requiring an antihistamine or corticosteroid treatment
an associated ENT disease
use of decongestants
nasal or ocular topical treatment
Study Design
Total Participants: 67
Study Start date:
August 01, 2003
Estimated Completion Date:
October 31, 2003